---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057131"
form_type: "8-K/A"
ticker: null
cik: "0001828522"
company_name: "eFFECTOR Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:55:37.076230+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# eFFECTOR Therapeutics enters $50M ATM equity offering with H.C. Wainwright, terminates Cantor agreement

## Summary
- Entered Sales Agreement with H.C. Wainwright & Co. to sell up to $50M of common stock via ATM offerings.
- Agent will receive a 3.0% commission on gross proceeds from any shares sold under the agreement.
- Terminated prior ATM agreement with Cantor Fitzgerald; 1,075,405 shares had been sold for $9.8M.
- No obligation to sell; sales will be made on Nasdaq Capital Market at prevailing market prices.

## SEC filing metadata
- accession: 0000950170-24-057131
- form_type: 8-K/A
- cik: 0001828522
- company_name: eFFECTOR Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/eftr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057131
- JSON: https://secwatch.observer/filing/0000950170-24-057131.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057131.txt

## Key facts
- Material Agreements
  eFFECTOR Therapeutics, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $9.8 million (effective 2024-05-09).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $9.8 million
  - Effective: 2024-05-09
  source text: On May 9, 2024, the Company terminated its Controlled Equity Offering SM Sales Agreement, dated September 1, 2022, with Cantor Fitzgerald & Co. (the “Prior Sales Agreement”), pursuant to which the Company was able sell shares of common stock in “at the market offerings” as defined by Rule 415 of the Securities Act.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm
- Material Agreements
  eFFECTOR Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $50.0 million (effective 2024-05-09).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: aggregate offering price of up to $50.0 million
  - Effective: 2024-05-09
  source text: On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50.0 million through the Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.